Company U.S. Stem Cell, Inc. Other OTC
Equities
USRM
US90350U1007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Autologous Cell Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 01/03/01 |
Mark Borman
CHM | Chairman | 69 | 01/09/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 05/17/05 |
Director/Board Member | 100 | 01/03/01 | |
Mark Borman
CHM | Chairman | 69 | 01/09/01 |
Miguel Tomás
CEO | Chief Executive Officer | 58 | 01/03/01 |
Sheldon Anderson
BRD | Director/Board Member | 73 | 28/13/28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 641,507,317 | 571,247,298 ( 89.05 %) | 0 | 89.05 % |
Company contact information
U.S. Stem Cell, Inc.
1560 Sawgrass Corporate Parkway 4th floor
33323-6217, Sunrise
+954 835 1500
http://www.us-stemcell.comSector
1st Jan change | Capi. | |
---|---|---|
+8.38% | 12TCr | |
+10.13% | 10TCr | |
-11.69% | 2.27TCr | |
+2.21% | 2.18TCr | |
-10.88% | 1.82TCr | |
-41.90% | 1.65TCr | |
-16.00% | 1.6TCr | |
+2.28% | 1.41TCr | |
+20.54% | 1.07TCr |